Omnicell, Inc. · NASDAQ:OMCL

Omnicell — Merger or Acquisition (July 2021)

8 slides from Omnicell's merger presentation, Jul 26, 2021

  1. Slide 1: Acquisition of FDS Amplicare Expands Omnicell's EnlivenHealth Solutions Platform

    Acquisition of FDS Amplicare Expands Omnicell’s EnlivenHealth Solutions Platform July 26, 2021

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement 2 This presentation contains forward-looking statements that involve risks and uncertainties, including statements regarding the timing of the consummation of the acquisition, the expected benefits of the acquisition of the FDS Amplicare business, including on Omnicell’s non-GA

  3. Slide 3: Compelling Strategic Benefits

    Compelling Strategic Benefits 3 • Advanced digital solutions, data analytics tools and automation capabilities optimize retail pharmacy workflows • Frees up pharmacists to practice at the top of their license, provide high value, revenue-generating services • The acquisition is expected to be accret

  4. Slide 4: FDS Amplicare Business at a Glance

    © 2021 Omnicell, Inc. Content is confidential and proprietary. 4 FDS Amplicare Business at a Glance Company Profile Based in Ft. Worth, TX. Provides SaaS solutions to help retail pharmacies grow profitably through proven financial, analytics and population health solutions Network of 15,000+ pharmac

  5. Slide 5: Transformation of Pharmacy

    Transformation of Pharmacy The COVID-19 pandemic accelerated major trends such as the digitization of care delivery and the growing role of retail pharmacy as an essential destination for trusted, accessible healthcare services. With this acquisition, Omnicell and its EnlivenHealth™ division are eve

  6. Slide 6: Directly Strengthens Key Autonomous Pharmacy Pillars

    Directly Strengthens Key Autonomous Pharmacy Pillars Safety Efficiency ComplianceFinancial People Automated workflow and optimized processes free up pharmacists to spend more time keeping patients healthy, happy and safe Automates manual, repetitive pharmacy tasks, saving pharmacists’ time Enables c

  7. Slide 7: Transaction Overview

    Transaction Overview 7 $177 million in cash, subject to customary adjustments Cash on hand Transaction Consideration Earnings Impact and Returns Sources of Financing High growth SaaS revenue business with attractive return profile Expected to be immediately accretive upon closing to Non-GAAP EBITDA

  8. Slide 8: Slide 8

Omnicell — Merger or Acquisition (July 2021) on 6ix